Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids

Translational Psychiatry

Volumn 5, Issue 1, 2015, Pages

  Amminger, G P ^a   Mechelli, A ^b   Rice, S ^a   Kim, S W ^c   Klier, C M ^d   McNamara, R K ^e   Berk, M ^f   McGorry, P D ^a   Schafer M R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Chonnam National University Medical School   (South Korea)

^d UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LINOLENIC ACID; OMEGA 3 FATTY ACID; PLACEBO; ALPHA TOCOPHEROL; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; FATTY ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; UNSATURATED FATTY ACID; VITAMIN;

ADOLESCENT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHROCYTE MEMBRANE; FEMALE; HIGH RISK POPULATION; HUMAN; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PREDICTIVE VALUE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ADULT; METABOLISM; MULTIVARIATE ANALYSIS; PSYCHOTIC DISORDERS; RISK; STATISTICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALPHA-LINOLENIC ACID; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; ERYTHROCYTE MEMBRANE; FATTY ACIDS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; LINEAR MODELS; LINOLEIC ACID; MALE; MULTIVARIATE ANALYSIS; PSYCHOTIC DISORDERS; RISK; TREATMENT OUTCOME; VITAMIN E; VITAMINS; YOUNG ADULT;

EID: 84927918496     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.134     Document Type: Article

References (47)

1. Gómez-Pinilla F. Brain foods: The effects of nutrients on brain function. Nat Rev Neurosci 2008; 9: 568-578
2. Piomelli D, Astarita G, Rapaka R. A neuroscientist's guide to lipidomics. Nat Rev Neurosci 2007; 8: 743-754
3. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011; 58: 2047-2067
4. Norris JM, Yin X, Lamb MM, Barriga K, Seifert J, Hoffman M et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 2007; 298: 1420-1428
5. Simopoulos AP. Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk. Exp Biol Med 2010; 235: 785-795
6. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30: 193-208
7. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-817
8. Hibbeln JR. Fish consumption and major depression. Lancet 1998; 351: 1213
9. Hedelin M, Löf M, Olsson M, Lewander T, Nilsson B, Hultman CM et al. Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33,000 women from the general population. BMC Psychiatry 2010; 26: 38
10. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M et al. Omega-fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006; 67: 1954-1967
11. Berger GE, Smesny S, Amminger GP. Bioactive lipids in schizophrenia. Int Rev Psychiatry 2006; 18: 85-98
12. Peet M. Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr J Psychiatry Relat Sci 2008; 45: 19-25
13. Fusar-Poli P, Berger G. Eicosapentaenoic acid interventions in schizophrenia. J Clin Psychopharmacol 2012; 32: 179-185
14. Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-154
15. Amminger GP, Schäfer MR, Klier CM, Slavik JM, Holzer I, Holub M et al. Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Mol Psychiatry 2012; 17: 1150-1152
16. Yung A, Phillips L, McGorry P, McFarlane C, Francey S, Harrigan S et al. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl 1998; 172: 14-20
17. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012; 69: 220-229
18. Yung A, Phillips L, Yuen H, McGorry P. Risk factors for psychosis in an ultra highrisk group: psychopathology and clinical features. Schizophr Res 2004; 67: 131-142
19. Amminger GP, Leicester S, Yung AR, Phillips LJ, Berger GE, Francey SM et al. Earlyonset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals. Schizophr Res 2006; 84: 67-76
20. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E et al. Prediction of psychosis in youth at high clinical risk: A multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65: 28-37
21. Nelson B, Yuen HP, Wood SJ, Lin A, Spiliotacopoulos D, Bruxner A et al. Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: The PACE 400 study. JAMA Psychiatry 2013; 70: 793-802
22. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 2011; 168: 800-805
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC, USA, 1994
24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
26. Smesny S, Milleit B, Hipler UC, Milleit C, Schäfer MR, Klier CM et al. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Mol Psychiatry 2014; 19: 317-324
27. Hoen WP, Lijmer JG, Duran M, Wanders RJ, van Beveren NJ, de Haan L et al. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: A meta-analysis. Psychiatry Res 2013; 207: 1-12
28. Assies J, Lieverse R, Vreken P, Wanders RJ, Dingemans PM, Linszen DH et al. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry 2001; 49: 510-522
29. Reddy RD, Keshavan MS, Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull 2004; 30: 901-911
30. Messamore E, Hoffman WF, Yao JK. Niacin sensitivity and the arachidonic acid pathway in schizophrenia. Schizophr Res 2010; 122: 248-256
31. Peet M, Horrobin DF, E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7-18
32. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebocontrolled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 1596-1598
33. Berger GE, Wood SJ, Wellard RM, Proffitt TM, McConchie M, Amminger GP et al. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology 2008; 33: 2467-2473
34. Yung AR, McGorry PD, Francey SM, Nelson B, Baker K, Phillips LJ et al. PACE: A specialised service for young people at risk of psychotic disorders. Med J Australia 2007; 187: S43-S46
35. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics 2000; 1: 465-480
36. Marquand A, Howard M, Brammer M, Chu C, Coen S, Mourão-Miranda J et al. Quantitative prediction of subjective pain intensity from whole-brain fMRI data using Gaussian processes. Neuroimage 2010; 49: 2178-2189
37. Sinclair AJ, Attar-Bashi NM, Li D. What is the role of alpha-linolenic acid for mammals? Lipids 2002; 37: 1113-1123
38. Brenna JT, Salem N, Sinclair AJ, Cunnane SC. International Society for the Study of Fatty Acids and Lipids, ISSFAL. Alpha-linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids 2009; 80: 85-91
39. Gracious BL, Chirieac MC, Costescu S, Finucane TL, Youngstrom EA, Hibbeln JR et al. Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord 2010; 12: 142-154
40. Burdge GC, Calder PC. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod Nutr Dev 2005; 45: 581-597
41. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 2013; 74: 400-409
42. Martinez M. Restoring the DHA levels in the brains of Zellweger patients. J Mol Neurosci 2001; 16: 309-316, discussion 317-321
43. Holub M. Der Einfluss von Fischöltherapie auf Vitamin E-Gehalt und Fettsäuremuster in der Erythrozytenmembran von psychiatrischen jugendlichen Patienten. Masters thesis. University Vienna, Austria 2006
44. Orrù G, Pettersson-Yeo W, Marquand AF, Sartori G, Mechelli A. Using Support Vector Machine to identify imaging biomarkers of neurological and psychiatric disease: A critical review. Neurosci Biobehav Rev 2012; 36: 1140-1152
45. Amminger GP, McGorry PD. Update on-3 polyunsaturated fatty acids in earlystage psychotic disorders. Neuropsychopharmacology 2012; 37: 309-310
46. Sethom MM, Fares S, Bouaziz N, Melki W, Jemaa R, Feki M et al. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2010; 83: 131-136
47. Anderson G, Maes M. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 5-19.